Does the media favor ARWR or RVMD?

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 23 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.62 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 12 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to NTRA or ARWR?

In the previous week, Natera had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 36 mentions for Natera and 28 mentions for Arrowhead Pharmaceuticals. Natera's average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to BIIB or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 18 mentions for Biogen. Biogen's average media sentiment score of 0.99 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 10 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ROIV or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Arrowhead Pharmaceuticals (ARWR) Competitors

$87.65 +1.82 (+2.12%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$88.32 +0.66 (+0.76%)

As of 08/7/2026 07:34 PM Eastern

Compare

ARWR vs. RVMD, NTRA, BIIB, ALNY, and ROIV

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? MarketBeat compares Arrowhead Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arrowhead Pharmaceuticals include Revolution Medicines (RVMD), Natera (NTRA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). These companies are all part of the "biotechnology" industry.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 23 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.62 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Revolution Medicines	N/A	-102.61%	-70.72%

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 11.05%. Revolution Medicines has a consensus price target of $153.05, indicating a potential downside of 25.39%. Given Arrowhead Pharmaceuticals' higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Natera?

Natera (NASDAQ:NTRA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

99.9% of Natera shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Natera has a net margin of -7.11% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Natera's return on equity of -11.82% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A

Natera presently has a consensus price target of $299.65, indicating a potential downside of 6.97%. Arrowhead Pharmaceuticals has a consensus price target of $97.33, indicating a potential upside of 11.05%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Natera has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, Natera had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 36 mentions for Natera and 28 mentions for Arrowhead Pharmaceuticals. Natera's average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Natera beats Arrowhead Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Biogen presently has a consensus target price of $224.61, indicating a potential upside of 8.02%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 11.05%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Biogen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.11	$1.29B	$5.65	36.80
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A

Biogen has a net margin of 8.32% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Biogen's return on equity of 11.18% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 18 mentions for Biogen. Biogen's average media sentiment score of 0.99 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.9% of Biogen shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A
Alnylam Pharmaceuticals	$3.71B	7.90	$313.75M	$5.38	40.74

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, suggesting a potential upside of 11.05%. Alnylam Pharmaceuticals has a consensus target price of $396.72, suggesting a potential upside of 80.98%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 37 mentions for Alnylam Pharmaceuticals and 28 mentions for Arrowhead Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of -0.02 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Arrowhead Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Roivant Sciences presently has a consensus target price of $34.77, suggesting a potential downside of 4.31%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, suggesting a potential upside of 11.05%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,164.44	-$299.77M	-$0.60	N/A
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Summary

Roivant Sciences and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.35B	$3.69B	$7.01B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-38.96	9.02	271.11	25.19
Price / Sales	14.89	1,303.70	597.74	81.69
Price / Cash	734.09	102.35	71.81	50.72
Price / Book	26.48	18.10	13.25	6.22
Net Income	-$1.63M	-$13.25M	$3.45B	$342.66M
7 Day Performance	3.54%	6.24%	4.67%	4.41%
1 Month Performance	4.36%	-3.50%	-1.28%	-1.11%
1 Year Performance	433.80%	61.28%	77.33%	23.99%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	1.6496 of 5 stars	$87.65 +2.1%	$97.33 +11.0%	+433.8%	$12.35B	$829.45M	N/A	400	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
RVMD Revolution Medicines	1.5975 of 5 stars	$182.45 -2.7%	$144.67 -20.7%	+486.1%	$39.87B	$11.58M	N/A	250	News Coverage Earnings Report Analyst Forecast
NTRA Natera	2.9346 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+112.0%	$38.35B	$2.31B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up
BIIB Biogen	3.9001 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+59.1%	$29.99B	$9.89B	35.72	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.7837 of 5 stars	$220.33 +7.2%	$402.67 +82.8%	-50.1%	$27.50B	$3.71B	40.95	2,770	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. RVMD, NTRA, BIIB, ALNY, and ROIV

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Natera?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. RVMD, NTRA, BIIB, ALNY, and ROIV

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Do institutionals and insiders hold more shares of ARWR or RVMD?

Does the media favor ARWR or RVMD?

Is ARWR or RVMD more profitable?

Which has higher valuation and earnings, ARWR or RVMD?

Do analysts prefer ARWR or RVMD?

Which has more risk & volatility, ARWR or RVMD?

Summary

How does Arrowhead Pharmaceuticals compare to Natera?

Do insiders & institutionals believe in NTRA or ARWR?

Is NTRA or ARWR more profitable?

Which has better earnings and valuation, NTRA or ARWR?

Do analysts recommend NTRA or ARWR?

Which has more risk & volatility, NTRA or ARWR?

Does the media refer more to NTRA or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Do analysts prefer BIIB or ARWR?

Which has more risk and volatility, BIIB or ARWR?

Which has higher valuation & earnings, BIIB or ARWR?

Is BIIB or ARWR more profitable?

Does the media refer more to BIIB or ARWR?

Do insiders and institutionals hold more shares of BIIB or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do insiders and institutionals hold more shares of ARWR or ALNY?

Which has higher valuation and earnings, ARWR or ALNY?

Which has more risk and volatility, ARWR or ALNY?

Is ARWR or ALNY more profitable?

Do analysts prefer ARWR or ALNY?

Does the media refer more to ARWR or ALNY?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Do analysts recommend ROIV or ARWR?

Do insiders and institutionals believe in ROIV or ARWR?

Which has preferable earnings & valuation, ROIV or ARWR?

Is ROIV or ARWR more profitable?

Does the media favor ROIV or ARWR?

Which has more volatility & risk, ROIV or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools